Otherwise, the majority of NSCLC patients harboring RET fusions exhibit low levels of PD-L1 expression and tumor mutation burden, resulting in suboptimal responses to immune checkpoint inhibitors (11). The gene discussed is CD274; the disease is non-small cell lung carcinoma.